» Articles » PMID: 29549269

Nonalcoholic Fatty Liver Disease Accelerates Kidney Function Decline in Patients with Chronic Kidney Disease: a Cohort Study

Overview
Journal Sci Rep
Specialty Science
Date 2018 Mar 18
PMID 29549269
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to investigate the association of nonalcoholic fatty liver disease (NAFLD) and its severity with the decline in kidney function in patients with chronic kidney disease (CKD). We conducted a cohort study of 1,525 CKD patients who underwent repeated health check-up examinations from January 2003 through December 2013. NAFLD was diagnosed by ultrasonography and its severity was assessed by the NAFLD fibrosis score. At baseline, the prevalence of NAFLD was 40.9%, and the mean estimated glomerular filtration rate (eGFR) was 59.1 ml/min/1.73 m. The average follow-up was 6.5 years. The age- and sex-adjusted decline in eGFR was greater in patients with NAFLD (-0.79% per year, 95% CI -1.31%, -0.27%) compared to those without it (0.30%, 95% CI -0.14%, 0.76%; p = 0.002). In multivariable adjusted models, the average difference in annual percent change in decline in eGFR comparing patients with NAFLD to those without NAFLD was -1.06% (-1.73%, -0.38%; p = 0.002). The decline in eGFR associated with NAFLD was greater in patients with higher NAFLD fibrosis score, in those with proteinuria or with low eGFR at baseline ( <45 ml/min/1.73 m), and in those who were smokers and hypertensive. Therefore, NAFLD is independently associated with CKD progression.

Citing Articles

The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease: A cross-sectional study.

Badawi R, Fahmy Abou Taira N, Hasby S, Elkhalawany W, Elrefaey W, Ahmed Khalf N Saudi Med J. 2024; 45(10):1034-1040.

PMID: 39379109 PMC: 11463562. DOI: 10.15537/smj.2024.45.10.20240393.


Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.

Gurun M, Brennan P, Handjiev S, Khatib A, Leith D, Dillon J PLoS One. 2024; 19(4):e0299507.

PMID: 38625981 PMC: 11020899. DOI: 10.1371/journal.pone.0299507.


The Intersection of Genetic Factors, Aberrant Nutrient Metabolism and Oxidative Stress in the Progression of Cardiometabolic Disease.

Butcko A, Putman A, Mottillo E Antioxidants (Basel). 2024; 13(1).

PMID: 38247511 PMC: 10812494. DOI: 10.3390/antiox13010087.


Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.

Karjoo S, Auriemma A, Fraker T, Bays H Obes Pillars. 2023; 3:100027.

PMID: 37990727 PMC: 10661876. DOI: 10.1016/j.obpill.2022.100027.


-, - and - Interactions Enhancement of Susceptibility to Non-Alcoholic Fatty Liver Disease.

Zhao J, Xu X, Wei X, Zhang S, Xu H, Wei X Biomedicines. 2023; 11(9).

PMID: 37760857 PMC: 10525902. DOI: 10.3390/biomedicines11092416.


References
1.
Kronenberg F . Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol. 2009; 5(12):677-89. DOI: 10.1038/nrneph.2009.173. View

2.
Armstrong M, Adams L, Canbay A, Syn W . Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2013; 59(3):1174-97. DOI: 10.1002/hep.26717. View

3.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

4.
Sabio G, Das M, Mora A, Zhang Z, Jun J, Ko H . A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science. 2008; 322(5907):1539-43. PMC: 2643026. DOI: 10.1126/science.1160794. View

5.
. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402. DOI: 10.1016/j.jhep.2015.11.004. View